Patents by Inventor Arnon Rosenthal

Arnon Rosenthal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
    Publication number: 20190315845
    Abstract: The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.
    Type: Application
    Filed: May 17, 2019
    Publication date: October 17, 2019
    Inventors: Arnon Rosenthal, Michael Leviten
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190315858
    Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
    Type: Application
    Filed: April 11, 2019
    Publication date: October 17, 2019
    Applicant: ALECTOR LLC
    Inventors: Kate Monroe, Tina Schwabe, Francesca Avogadri-Connors, Ilaria Tassi, Helen Lam, Arnon Rosenthal
  • Anti-sortilin antibodies and methods of use thereof
    Patent number: 10428150
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: October 1, 2019
    Assignee: Alector LLC
    Inventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas
  • Anti-SIRP-Alpha Antibodies and Methods of Use Thereof
    Publication number: 20190275150
    Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.
    Type: Application
    Filed: December 8, 2017
    Publication date: September 12, 2019
    Applicant: Alector LLC
    Inventors: Andrew Pincetic, Arnon Rosenthal, Seung-Joo Lee
  • CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
    Publication number: 20190233496
    Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent a neurological disease, disorder, or injury.
    Type: Application
    Filed: September 4, 2018
    Publication date: August 1, 2019
    Applicant: Alector LLC
    Inventor: Arnon ROSENTHAL
  • ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
    Publication number: 20190211084
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Application
    Filed: January 4, 2019
    Publication date: July 11, 2019
    Inventors: Arnon Rosenthal, Michael Leviten
  • Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide
    Patent number: 10329343
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: June 25, 2019
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Joerg Zeller, Kristian Todd Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
    Patent number: 10323086
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: June 18, 2019
    Assignee: Rinat Neuroscience Corp.
    Inventors: Arnon Rosenthal, David Louis Shelton, Patricia Ann Walicke
  • TRANSGENIC MICE EXPRESSING HUMAN TREM PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20190174730
    Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from TREM1, TREML1, TREM2, TREML2, and TREML4, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human TREM immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human TREM repertoire.
    Type: Application
    Filed: December 12, 2018
    Publication date: June 13, 2019
    Applicant: Alector LLC
    Inventors: Ilaria Tassi, Asa Abeliovich, Seung-Joo Lee, Arnon Rosenthal, Tina Schwabe
  • Humanized anti-complement factor C1Q antibodies
    Patent number: 10316081
    Abstract: The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: June 11, 2019
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Anti-sortilin antibodies and methods of use thereof
    Patent number: 10308718
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: June 4, 2019
    Assignee: ALECTOR LLC
    Inventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
  • ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190127475
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: August 20, 2018
    Publication date: May 2, 2019
    Applicant: Alector LLC
    Inventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS
  • Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
    Publication number: 20190092841
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: April 18, 2018
    Publication date: March 28, 2019
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190085076
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: June 11, 2016
    Publication date: March 21, 2019
    Applicant: ALECTOR LLC
    Inventors: Arnon ROSENTHAL, Kate MONROE, Francesca AVOGADRI-CONNORS
  • ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190085084
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: September 18, 2018
    Publication date: March 21, 2019
    Applicant: Alector LLC
    Inventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas
  • Anti-complement factor C1q antibodies and uses thereof
    Patent number: 10227398
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: March 12, 2019
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190062433
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: August 8, 2018
    Publication date: February 28, 2019
    Applicant: ALECTOR LLC
    Inventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas
  • ANTI-SIGLEC-9 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190062427
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 28, 2019
    Applicants: ALECTOR LLC, ALECTOR LLC
    Inventors: Arnon ROSENTHAL, Kate MONROE, Seung-Joo LEE
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190040130
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: August 3, 2018
    Publication date: February 7, 2019
    Applicant: ALECTOR LLC
    Inventors: Tina SCHWABE, Eric BROWN, Philip KONG, IIaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL, Robert PEJCHAL, Nels P. NIELSON
  • ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190040131
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: August 3, 2018
    Publication date: February 7, 2019
    Applicant: ALECTOR LLC
    Inventors: Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal